2-Ethoxy-ethylisocyanat | 7019-12-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Ethoxy-ethylisocyanat
• 英文别名: 1-Ethoxy-2-isocyanatoethane
• CAS: 7019-12-7
• 化学式: C₅H₉NO₂
• 分子量: 115.132
• InChiKey: BPMWGYVGVKSICP-UHFFFAOYSA-N

物化性质

• 沸点：
  140-142 °C
• 密度：
  0.95±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Ethoxy-ethylisocyanat 在 吡啶 、 sodium ethanolate 、 potassium carbonate 、 溶剂黄146 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 135.25h， 生成 3-(2-ethoxyethyl)-1-(2-methoxyethyl)-5-methyl-6-[(2-oxoimidazolidin-1-yl)methyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR

  摘要：

  本申请涉及具有特定类型的(氮杂杂环基)甲基取代基的新型噻吩并[2,3-d]嘧啶-2,4-二酮（“噻吩尿嘧啶”）衍生物，以及其制备方法，单独或组合用于治疗和/或预防疾病，以及用于生产用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防肺部和心血管疾病以及癌症的用途。

  公开号：

  US20180065981A1
• 作为产物：
  描述：

  光气 、 1-p-Tosyl-3-(2-ethoxyethyl)harnstoff 以 邻二氯苯 为溶剂， 生成 2-Ethoxy-ethylisocyanat
  参考文献：
  名称：

  Ulrich,H.; Sayigh,A.A.R., Angewandte Chemie, 1966, vol. 78, p. 761 - 769

  摘要：

  DOI：

文献信息

• Certain 2-carbamoyl-1,2,4-thiadiazole-3-one herbicides
  申请人：Roussel Uclaf

  公开号：US04067720A1

  公开（公告）日：1978-01-10

  Novel thiadiazoles of the formula ##STR1## wherein R is selected from the group consisting of alkoxy of 1 to 8 carbon atoms, cycloalkyloxy of 3 to 7 carbon atoms, alkylthio of 1 to 8 carbon atoms optionally substituted with carbalkoxy of 2 to 5 carbon atoms, alkenylthio of 2 to 4 carbon atoms, ##STR2## and benzyloxy, benzylthio, benzyl and phenyl, all aryl being optionally substituted with 1 to 2 members of the group consisting of chlorine, bromine, alkyl of 1 to 3 carbon atoms and alkoxy of 1 to 3 carbon atoms, Z and Z.sub.1 are alkyl of 1 to 4 carbon atoms and R.sub.1 is selected from the group consisting of alkyl of 1 to 6 carbon atoms optionally substituted with a member of the group consisting of chlorine, bromine and alkyloxy of 1 to 4 carbon atoms, phenyl optionally substituted with 1 to 2 members of the group consisting of bromine, chlorine, alkyl of 1 to 3 carbon atoms and alkoxy of 1 to 3 carbon atoms, alkenyl of 2 to 4 carbon atoms optionally substituted with at least one member of the group consisting of chlorine and alkoxy of 1 to 3 carbon atoms, ##STR3## and carbalkoxy of 2 to 6 carbon atoms and X is selected from the group consisting of alkyl of 1 to 4 carbon atoms and alkenyl of 2 to 4 carbon atoms, both optionally substituted with at least one chlorine having herbicidal properties and novel intermediates.

  化合物的式子为：##STR1## 其中R从以下组中选择：1至8个碳原子的烷氧基，3至7个碳原子的环烷氧基，1至8个碳原子的烷基硫醚，可选择用2至5个碳原子的碳基氧代烷基取代的1至8个碳原子的烷基硫醚，2至4个碳原子的烯基硫醚，##STR2## 苯甲氧基，苯甲硫醚，苯甲基和苯基，所有芳基都可以选择用1至2个卤素，1至3个碳原子的烷基和1至3个碳原子的烷氧基中的一种或两种取代，Z和Z.sub.1是1至4个碳原子的烷基，R.sub.1从以下组中选择：1至6个碳原子的烷基，可选择用卤素、溴素和1至4个碳原子的烷氧基中的一种取代的苯基，可选择用1至3个碳原子的烷基和1至3个碳原子的烷氧基中的一种或两种取代的烯基，##STR3## 和2至6个碳原子的碳基氧代烷基，X从以下组中选择：1至4个碳原子的烷基和2至4个碳原子的烯基，两者都可以选择用至少一种具有除草特性的氯取代，还有新的中间体。
• 5-Fluorouracil derivatives, and their pharmaceutical compositions
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04349552A1

  公开（公告）日：1982-09-14

  A compound of the formula: ##STR1## wherein R is a bridged alicyclic group selected from the group consisting of norbornyl, norbornenyl, bicyclo[2,2,2]-heptyl and adamantyl optionally substituted by at least one substituent selected from the group consisting of lower alkyl, carboxy, lower alkoxycarbonyl, alkylidenedioxy, N,N-di(lower)alkylcarbamoyl, amino, loweralkoxycarbonylamino and halogen. The present compound is useful in the therapeutic treatment of cancer in human beings and animals.

  分子式为：##STR1## 其中R是从诺博烯基，诺博烯基，双环[2,2,2]-庚烷基和金刚烷基中选择的桥式脂环基，可以选择性地被至少一种取代基所取代，所述取代基选择自下列群体：低碳基，羧基，低碳基氧羰基，烷基二氧基，N，N-二（低）烷基氨基甲酰基，氨基，低碳基氧羰基氨基和卤素。该化合物在治疗人类和动物的癌症中有用。
• The structure–activity relationship of urea derivatives as anti-tuberculosis agents
  作者：Joshua R. Brown、Elton J. North、Julian G. Hurdle、Christophe Morisseau、Jerrod S. Scarborough、Dianqing Sun、Jana Korduláková、Michael S. Scherman、Victoria Jones、Anna Grzegorzewicz、Rebecca M. Crew、Mary Jackson、Michael R. McNeil、Richard E. Lee

  DOI：10.1016/j.bmc.2011.07.034

  日期：2011.9

  The treatment of tuberculosis is becoming more difficult due to the ever increasing prevalence of drug resistance. Thus, it is imperative that novel anti-tuberculosis agents, with unique mechanisms of action, be discovered and developed. The direct anti-tubercular testing of a small compound library led to discovery of adamantyl urea hit compound 1. In this study, the hit was followed up through the synthesis of an optimization library. This library was generated by systematically replacing each section of the molecule with a similar moiety until a clear structure-activity relationship was obtained with respect to antitubercular activity. The best compounds in this series contained a 1-adamantyl-3-phenyl urea core and had potent activity against Mycobacterium tuberculosis plus an acceptable therapeutic index. It was noted that the compounds identified and the pharmacophore developed is consistent with inhibitors of epoxide hydrolase family of enzymes. Consequently, the compounds were tested for inhibition of representative epoxide hydrolases: M. tuberculosis EphB and EphE; and human soluble epoxide hydrolase. Many of the optimized inhibitors showed both potent EphB and EphE inhibition suggesting the antitubercular activity is through inhibition of multiple epoxide hydrolase enzymes. The inhibitors also showed potent inhibition of humans soluble epoxide hydrolase, but limited cytotoxicity suggesting that future studies must be towards increasing the selectivity of epoxide hydrolase inhibition towards the M. tuberculosis enzymes. (C) 2011 Elsevier Ltd. All rights reserved.
• HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20180065981A1

  公开（公告）日：2018-03-08

  The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.

  本申请涉及具有特定类型的(氮杂杂环基)甲基取代基的新型噻吩并[2,3-d]嘧啶-2,4-二酮（“噻吩尿嘧啶”）衍生物，以及其制备方法，单独或组合用于治疗和/或预防疾病，以及用于生产用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防肺部和心血管疾病以及癌症的用途。
• Ulrich,H.; Sayigh,A.A.R., Angewandte Chemie, 1966, vol. 78, p. 761 - 769
  作者：Ulrich,H.、Sayigh,A.A.R.

  DOI：——

  日期：——